How FDA’s June 2026 Draft Guidance Lets Genome Editing Sponsors Reuse CMC, Nonclinical, Bioinformatics, and Clinical Data Across Programs, and Where the Agency Still Wants Product Specific Work Done

FDA just dropped a draft guidance that every genome editing platform company should read. The question it answers: when can you stop regenerating data you already proved on a prior program?

The core idea is a split between independent and dependent attributes. Analytical methods, cleanroom classifications, delivery vehicle biodistribution - these travel …